Bionexus Gene Lab announces board approval of Ethereum treasury strategy

BioNexus Gene Lab’s (BGLC) Board of Directors has formally approved the Company’s new Ethereum (ETH)-focused treasury strategy. Concurrently, BGLC has released its Ethereum Strategy Whitepaper, detailing the rationale behind the company’s decision and the broader significance of Ethereum as a financial infrastructure asset. The whitepaper provides insight into Ethereum’s institutional adoption, staking capabilities, and upcoming protocol upgrades, which reinforce its long-term value and corporate utility. Following extensive analysis, the Board has determined that Ethereum presents a strategic treasury management solution due to its: Institutional credibility: Adoption among major financial institutions, and exchange traded funds. Yield-generation capabilities: Ethereum’s Proof-of-Stake system enables passive income through staking. Financial infrastructure dominance: Ethereum underpins trillions of dollars in stablecoin transactions annually. Long-term scalability: Upcoming Ethereum upgrades, such as the major Pectra upgrade, enhance efficiency and adoption.